Document is current
Any future updates will be listed below
-
Authors
Hanna, Michael G https://orcid.org/0000-0002-1975-0501
Rodriguez Cruz, Hely O https://orcid.org/0009-0005-7155-5366
Fujise, Kenshiro
Wu, Yumei
Xu, C Shan
Pang, Song
Li, Zhuonging
Monetti, Mara https://orcid.org/0009-0006-9778-9010
De Camilli, Pietro https://orcid.org/0000-0001-9045-0723
-
Funding
Funding for this research was provided by:
HHS | NIH | National Institute on Drug Abuse (DA018343)
HHS | NIH | National Institute of Neurological Disorders and Stroke (NS36251)
Aligning Science Across Parkinson's (ASAP-000580)
HHS | NIH | NCI | Center for Cancer Research (CA008748)
- License Information
-
More Information
Article History
Received: 3 April 2025
Revised: 25 July 2025
Accepted: 1 August 2025
First Online: 11 September 2025
Disclosure and competing interests statement
: PDC is a member of the Scientific Advisory Board of Casma Therapeutics. The authors declare no competing interests.
